Bottom line
Orforglipron is chemically different from Wegovy pill — a non-peptide small molecule. That matters because it doesn't need a fasting window, is much cheaper to manufacture, and could push oral GLP-1 pricing toward $100/mo or less.
Why non-peptide matters
Peptide drugs (semaglutide, tirzepatide) are expensive: $50-80/mo just in manufacturing cost. Small molecules like orforglipron cost under $10/mo to make at scale — same economics as statins.
Phase 3 results
ATTAIN-1 (72 weeks): ~14.7% average weight loss. Behind Zepbound but tied with Wegovy injectable.
Who should care
Cash-pay patients (price floor may drop to $99/mo within a year of launch), anyone on Wegovy pill, patients who hate injections but wouldn't pay current oral prices.
Timeline
Phase 3 completed Q1 2026. FDA filing expected Q2 2026. Launch target late 2026 / early 2027.
What to do now
Don't wait. Start with what's available today. Switching to orforglipron later will be straightforward if it makes sense.